Popular Articles

In A Chemical Library, Yale Researchers Find Keys To Cell Movement
Rummaging through a biotechnology company"s chemical closet, Yale University researchers found two molecules that will allow scientists to better study how cells move. The study in the journal Nature, published online Aug. 2, describes how two small molecules discovered by Cytokinetics Inc. block the action of a key complex that directs the assembly of actin filaments, which produce the force to help cells move. The target of these inhibitors is the Arp2/3 complex, a cellular component so vital that cells die without it. This dependence has made it challenging to learn exactly which cellular processes depend upon the complex.

Veterinary Practices In UK Need Good Access To Occupational Health
Staff working in UK veterinary practices lack access to good occupational health advice warns a new study published in the scientific journal, Occupational Medicine. The research, the first published benchmark of occupational health risk management by vet practices in the UK, showed that despite veterinary surgeons and nurses being exposed to many occupational hazards less than a third of practices had trained staff in health and safety and only 14% sought advice from occupational health professionals.
News of the day
Longevity And Mediterranean Diet Link Could Be Due To Specific Foods
New research from scientists in the US and Greece suggests that the health and longevity effects of the Mediterranean Diet are more strongly
Public Health

International Stem Cell Corporation Reports Positive Pre-Clinical Trial Results From Human Corneal Epithelial Cells

International Stem Cell Corporation (OTCBB:ISCO), the first company to perfect a method of creating human "parthenogenetic" stem cells from unfertilized eggs, has received positive early results from animal trials designed to improve photorefractive keratectomy (PRK), a form of corrective laser eye surgery that offers an improved alternative to LASIK. PRK is generally thought to be safer and produce better long-term results than LASIK, but has not been used as frequently because of patient discomfort following surgery and a longer healing time. By combining ISCO"s human corneal cells with a proprietary surgical device developed by Paul H. Chen, M.D., who is conducting the trials, ISCO and Dr. Chen believe that cellular enhanced PRK can replace LASIK for many of the hundreds of thousands of patients who now use LASIK. The first stage animal trials just completed demonstrated that ISCO"s corneal cells manufactured by ISCO"s subsidiary, Lifeline Cell Technology, encouraged corneal-defect healing in the animals. The trials are the first step toward gaining Food and Drug Administration (FDA) approval to test the efficacy of using ISCO"s cells to improve healing after corneal surgery, and could result in the first FDA approved use of human cells produced by ISCO. Jeffrey Janus, President of ISCO and CEO of Lifeline, noted that "The cells used in these trials are derived from donated human tissue processed using proprietary techniques devised by ISCO"s subsidiary, Lifeline Cell Technology. However, ISCO"s parthenogenic stem cells can also produce human corneal cells. Corneal cells derived from ISCO"s parthenogenetic stem cells may provide a consistent and reliable of corneal cells that could eliminate entirely the need for donated human tissues." This work is being done in collaboration with Dr. Chen, who has developed the cell transfer technology. Dr. Chen is an eye surgeon at North County Laser Eye Associates, and he is on staff at Scripps Memorial La Jolla and Scripps Encinitas Hospitals. For more news and information on International Stem Cell Corporation please visit http://www.IRGnews.com/coi/ISCO where you can find the CEO"s video, a fact sheet on the company, investor presentations, and more. International Stem Cell Corporation (ISCO.OB)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):